Shattuck Labs Inc (STTK) - Net Assets
Based on the latest financial reports, Shattuck Labs Inc (STTK) has net assets worth $93.24 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($100.33 Million) and total liabilities ($7.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Shattuck Labs Inc (STTK) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $93.24 Million |
| % of Total Assets | 92.93% |
| Annual Growth Rate | N/A |
| 5-Year Change | -74.3% |
| 10-Year Change | N/A |
| Growth Volatility | 13.12 |
Shattuck Labs Inc - Net Assets Trend (2018–2024)
This chart illustrates how Shattuck Labs Inc's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Shattuck Labs Inc for the complete picture of this company's asset base.
Annual Net Assets for Shattuck Labs Inc (2018–2024)
The table below shows the annual net assets of Shattuck Labs Inc from 2018 to 2024. For live valuation and market cap data, see how much is Shattuck Labs Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $79.63 Million | -44.97% |
| 2023-12-31 | $144.71 Million | -17.85% |
| 2022-12-31 | $176.16 Million | -35.19% |
| 2021-12-31 | $271.79 Million | -12.29% |
| 2020-12-31 | $309.86 Million | +996.90% |
| 2019-12-31 | $-34.55 Million | -211.78% |
| 2018-12-31 | $-11.08 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shattuck Labs Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 37021200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.01% |
| Other Comprehensive Income | $2.00K | 0.00% |
| Other Components | $461.34 Million | 579.38% |
| Total Equity | $79.63 Million | 100.00% |
Shattuck Labs Inc Competitors by Market Cap
The table below lists competitors of Shattuck Labs Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Synnex (Thailand) Public Company Limited
BK:SYNEX
|
$244.31 Million |
|
GoldMining Inc
TO:GOLD
|
$244.31 Million |
|
Eagle High Plantations Tbk
JK:BWPT
|
$244.37 Million |
|
Mecaro Co. Ltd
KQ:241770
|
$244.38 Million |
|
Formosa Oilseed Processing Co Ltd
TW:1225
|
$244.25 Million |
|
Roda Vivatex Tbk
JK:RDTX
|
$244.13 Million |
|
Pioneer High Income Closed Fund
NYSE:PHT
|
$244.12 Million |
|
Infotel SA
PA:INF
|
$244.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shattuck Labs Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 144,705,000 to 79,626,000, a change of -65,079,000 (-45.0%).
- Net loss of 75,410,000 reduced equity.
- Share repurchases of 17,000 reduced equity.
- Other comprehensive income decreased equity by 2,000.
- Other factors increased equity by 10,350,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-75.41 Million | -94.71% |
| Share Repurchases | $17.00K | -0.02% |
| Other Comprehensive Income | $-2.00K | -0.0% |
| Other Changes | $10.35 Million | +13.0% |
| Total Change | $- | -44.97% |
Book Value vs Market Value Analysis
This analysis compares Shattuck Labs Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.46x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.74 | $6.99 | x |
| 2019-12-31 | $-0.83 | $6.99 | x |
| 2020-12-31 | $7.42 | $6.99 | x |
| 2021-12-31 | $6.47 | $6.99 | x |
| 2022-12-31 | $4.16 | $6.99 | x |
| 2023-12-31 | $3.40 | $6.99 | x |
| 2024-12-31 | $1.57 | $6.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shattuck Labs Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -94.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1318.13%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.14x
- Recent ROE (-94.71%) is below the historical average (-34.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -32.92% | 0.33x | 0.00x | $-6.28 Million |
| 2019 | 0.00% | -242.56% | 0.22x | 0.00x | $-20.53 Million |
| 2020 | -11.44% | -356.71% | 0.03x | 1.13x | $-66.42 Million |
| 2021 | -16.55% | -149.83% | 0.10x | 1.10x | $-72.15 Million |
| 2022 | -57.09% | -15423.47% | 0.00x | 1.17x | $-118.18 Million |
| 2023 | -60.33% | -5268.44% | 0.01x | 1.10x | $-101.77 Million |
| 2024 | -94.71% | -1318.13% | 0.06x | 1.14x | $-83.37 Million |
Industry Comparison
This section compares Shattuck Labs Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shattuck Labs Inc (STTK) | $93.24 Million | 0.00% | 0.08x | $244.26 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Shattuck Labs Inc
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inf… Read more